• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

林多抗肽,一种针对表皮生长因子受体变体III(EGFRvIII)的14聚体注射用肽疫苗,用于多形性胶质母细胞瘤的潜在治疗。

Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.

作者信息

Del Vecchio Catherine A, Wong Albert J

机构信息

Stanford University, 300 Pasteur Drive, Edwards R213, Stanford, CA 94305, USA.

出版信息

Curr Opin Mol Ther. 2010 Dec;12(6):741-54.

PMID:21154166
Abstract

Celldex Therapeutics is developing rindopepimut (CDX-110), a 14-mer injectable peptide vaccine for the potential treatment of glioblastoma multiforme (GBM). Rindopepimut specifically targets a novel junctional epitope of the EGFR deletion mutant EGFRvIII, which is a constitutively active receptor that is expressed in approximately 60 to 70% of patients with GBM. EGFRvIII expression is correlated with worse prognosis and reduced overall survival. Importantly, EGFRvIII is not expressed in normal brain tissue, making it an excellent therapeutic target. Preclinical studies demonstrated lasting tumor regression and increased survival times, as well as efficient generation of EGFRvIII-specific humoral and cellular immune responses, in animals expressing EGFRvIII and vaccinated with rindopepimut. Phase I and II clinical trials in patients with GBM demonstrated significantly increased median time to progression and overall survival time in those vaccinated with rindopepimut compared with matched historical controls. Only limited side effects have been observed in patients. Given these results, rindopepimut is an extremely promising therapy for patients with GBM. Phase I and II clinical trials in patients with GBM were ongoing at the time of publication. In the future, it may be beneficial to combine rindopepimut with other treatment modalities to further prolong survival.

摘要

赛尔迪克斯治疗公司正在研发rindopepimut(CDX - 110),这是一种由14个氨基酸组成的注射用肽疫苗,用于潜在治疗多形性胶质母细胞瘤(GBM)。Rindopepimut特异性靶向表皮生长因子受体(EGFR)缺失突变体EGFRvIII的一个新的连接表位,EGFRvIII是一种组成型激活受体,在约60%至70%的GBM患者中表达。EGFRvIII的表达与较差的预后和缩短的总生存期相关。重要的是,EGFRvIII在正常脑组织中不表达,使其成为一个理想的治疗靶点。临床前研究表明,在表达EGFRvIII并接种rindopepimut的动物中,可出现持久的肿瘤消退和生存期延长,以及高效产生EGFRvIII特异性体液和细胞免疫反应。针对GBM患者的I期和II期临床试验表明,与匹配的历史对照相比,接种rindopepimut的患者的中位进展时间和总生存期显著延长。在患者中仅观察到有限的副作用。鉴于这些结果,rindopepimut对GBM患者来说是一种极有前景的治疗方法。在发表本文时,针对GBM患者的I期和II期临床试验正在进行。未来,将rindopepimut与其他治疗方式联合使用可能有助于进一步延长生存期。

相似文献

1
Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.林多抗肽,一种针对表皮生长因子受体变体III(EGFRvIII)的14聚体注射用肽疫苗,用于多形性胶质母细胞瘤的潜在治疗。
Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
2
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.一项关于rindopepimut(CDX - 110)在新诊断胶质母细胞瘤中的II期多中心试验:ACT III研究。
Neuro Oncol. 2015 Jun;17(6):854-61. doi: 10.1093/neuonc/nou348. Epub 2015 Jan 13.
3
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.里登肽联合替莫唑胺治疗新诊断的表皮生长因子受体VIII 表达型胶质母细胞瘤患者(ACT IV):一项随机、双盲、国际 III 期试验。
Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23.
4
Prospect of rindopepimut in the treatment of glioblastoma.rindopepimut治疗胶质母细胞瘤的前景
Expert Opin Biol Ther. 2017 Apr;17(4):507-513. doi: 10.1080/14712598.2017.1299705. Epub 2017 Mar 5.
5
Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.针对表皮生长因子受体变体 III:恶性神经胶质瘤的肿瘤特异性肽疫苗接种。
Expert Rev Vaccines. 2012 Feb;11(2):133-44. doi: 10.1586/erv.11.177.
6
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.rindopepimut:一种用于治疗多形性胶质母细胞瘤的有前景的免疫疗法。
Immunotherapy. 2014;6(6):679-90. doi: 10.2217/imt.14.21.
7
Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma.琳多西肽:关于其治疗EGFRvIII阳性胶质母细胞瘤治疗潜力的循证综述
Core Evid. 2012;7:93-103. doi: 10.2147/CE.S29001. Epub 2012 Sep 14.
8
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.表皮生长因子受体和EGFRvIII对多形性胶质母细胞瘤患者的预后影响
Clin Cancer Res. 2005 Feb 15;11(4):1462-6. doi: 10.1158/1078-0432.CCR-04-1737.
9
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.表皮生长因子受体在多形性胶质母细胞瘤患者中的预后价值
Cancer Res. 2003 Oct 15;63(20):6962-70.
10
The EGFRvIII variant in glioblastoma multiforme.多形性胶质母细胞瘤中的表皮生长因子受体III型变异体
J Clin Neurosci. 2009 Jun;16(6):748-54. doi: 10.1016/j.jocn.2008.12.005. Epub 2009 Mar 25.

引用本文的文献

1
Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy.脑肿瘤免疫治疗反应的代谢组学监测
Front Oncol. 2021 Jun 3;11:691246. doi: 10.3389/fonc.2021.691246. eCollection 2021.
2
Novel Treatment Strategies for Glioblastoma.胶质母细胞瘤的新型治疗策略
Cancers (Basel). 2020 Oct 8;12(10):2883. doi: 10.3390/cancers12102883.
3
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells.通过基因工程嵌合抗原受体T细胞靶向癌症干细胞
Front Genet. 2020 Apr 22;11:312. doi: 10.3389/fgene.2020.00312. eCollection 2020.
4
Genomic alterations of ERBB receptors in cancer: clinical implications.癌症中ERBB受体的基因组改变:临床意义
Oncotarget. 2017 Nov 30;8(69):114371-114392. doi: 10.18632/oncotarget.22825. eCollection 2017 Dec 26.
5
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.英国癌症研究中心开展的IMA950(新型多肽治疗性疫苗)用于新诊断胶质母细胞瘤患者的首次人体I期试验。
Clin Cancer Res. 2016 Oct 1;22(19):4776-4785. doi: 10.1158/1078-0432.CCR-16-0506. Epub 2016 May 25.
6
A Hybrid Peptide PTS that Facilitates Transmembrane Delivery and Its Application for the Rapid In vivo Imaging via Near-Infrared Fluorescence Imaging.一种促进跨膜递送的杂合肽PTS及其通过近红外荧光成像在体内快速成像中的应用。
Front Pharmacol. 2016 Mar 8;7:51. doi: 10.3389/fphar.2016.00051. eCollection 2016.
7
Molecular heterogeneity in glioblastoma: potential clinical implications.胶质母细胞瘤中的分子异质性:潜在的临床意义。
Front Oncol. 2015 Mar 3;5:55. doi: 10.3389/fonc.2015.00055. eCollection 2015.
8
Glioblastoma multiforme: State of the art and future therapeutics.多形性胶质母细胞瘤:现状与未来治疗方法
Surg Neurol Int. 2014 May 8;5:64. doi: 10.4103/2152-7806.132138. eCollection 2014.
9
Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.针对由表皮生长因子受体变体 III 定义的胶质母细胞瘤癌症干细胞群体。
Cancer Res. 2014 Feb 15;74(4):1238-49. doi: 10.1158/0008-5472.CAN-13-1407. Epub 2013 Dec 23.
10
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?鼻腔内递药制剂对抗脑部疾病:治疗 GBM 的新机会?
Cancers (Basel). 2013 Aug 14;5(3):1020-48. doi: 10.3390/cancers5031020.